Heart Issues Linked to Cosentyx Treatment
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, carries warnings for inflammatory bowel disease (IBD) that can indirectly affect heart health through systemic inflammation. More directly, post-marketing reports and clinical data highlight cardiovascular risks, including new-onset or worsening heart failure and inflammatory heart conditions.[1][2]
What Inflammatory Heart Conditions Has It Revealed?
Rare cases of new-onset inflammatory disorders like sarcoidosis (affecting lungs and heart), vasculitis, lupus nephritis, and inflammatory bowel disease have emerged during treatment. These can manifest as myocarditis or pericarditis, revealing underlying or treatment-triggered cardiac inflammation not previously detected.[1][3]
Reports of Heart Failure and Inflammatory Bowel Disease
Labeling notes exacerbations of Crohn's disease and ulcerative colitis, which correlate with higher cardiovascular event risks due to chronic inflammation. Clinical trials reported heart failure in <1% of patients, often worsening pre-existing cases; post-approval surveillance flagged additional cardiac inflammatory events.[1][2]
How Common Are These Cardiac Revelations?
Incidence remains low: heart failure or cardiac events in 0.1-0.5% across trials, with inflammatory revelations mostly post-marketing (exact rates undisclosed). Risks rise in patients with baseline heart conditions or IBD history.[1][4]
Monitoring and Patient Warnings
Prescribers monitor for heart failure symptoms (shortness of breath, swelling) and discontinue if confirmed. Patients with cardiovascular risk factors face heightened scrutiny; FDA label advises against use in active IBD.[1][2]
Sources:
[1] Cosentyx Prescribing Information (Novartis)
[2] FDA Label for Secukinumab
[3] Drugs.com Side Effects Database
[4] ClinicalTrials.gov Summaries for NCT01695239